Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Titel:
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Auteur:
Garcia-Manero, Guillermo Fenaux, Pierre Al-Kali, Aref Baer, Maria R Sekeres, Mikkael A Roboz, Gail J Gaidano, Gianluca Scott, Bart L Greenberg, Peter Platzbecker, Uwe Steensma, David P Kambhampati, Suman Kreuzer, Karl-Anton Godley, Lucy A Atallah, Ehab Collins Jr, Robert Kantarjian, Hagop Jabbour, Elias Wilhelm, Francois E Azarnia, Nozar Silverman, Lewis R